Core Viewpoint - The company held its second extraordinary general meeting of shareholders in 2025, where all proposed resolutions were approved without any objections [1][2]. Meeting Details - The meeting took place on September 22, 2025, at 13:30, with both on-site and online voting options available [3][4]. - The total number of shares with voting rights was 595,000,033 [5]. - A total of 152 shareholders participated, representing 487,150,449 shares, which is 81.8740% of the total voting shares [6]. Shareholder Participation - Among the participating shareholders, 150 were small shareholders, representing 28,150,449 shares, or 4.7312% of the total voting shares [7]. - The meeting was presided over by the chairman, Mr. An Kang, and was witnessed by lawyers from Anhui Chengyi Law Firm, who provided a legal opinion confirming the meeting's compliance with regulations [7][8]. Voting Results - The proposal regarding the 2025 mid-term profit distribution plan was approved with 486,923,499 votes in favor, accounting for 99.9534% of the valid votes cast [8]. - Small shareholders voted 27,923,499 shares in favor, representing 99.1938% of the small shareholders' valid votes [8]. Legal Opinion - The legal advisors confirmed that the meeting's procedures, participant qualifications, proposals, voting processes, and results were all in accordance with legal and regulatory requirements [8]. Documents for Reference - The resolutions from the second extraordinary general meeting and the legal opinion from Anhui Chengyi Law Firm are available for review [9].

Core Viewpoint - The company, Hualan Biological, has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, a treatment for type 2 diabetes, and is preparing to initiate Phase III trials [2] Group 1 - The company has obtained complete efficacy and safety data from the completed clinical trials [2] - Hualan Biological is applying for a new indication for overweight/obesity and has communicated with the National Medical Products Administration, which has accepted the registration application [2]

Core Viewpoint - The company, Hualan Biological Engineering, announced that its interim dividend will be completed within two months after being approved at the shareholders' meeting [2] Group 1 - The company responded to investor inquiries on September 22 regarding its interim dividend plans [2]

Core Viewpoint - The company, Hualan Biological Engineering, emphasizes its commitment to a stable dividend policy while sharing operational achievements with shareholders, aligning with regulatory guidelines to enhance long-term investment value and investor satisfaction [2] Group 1 - The company has consistently implemented a prudent dividend policy, ensuring that shareholders benefit from the company's stable and high-quality development [2] - The recent cash dividend plan is designed to reflect the principles of stability, sustainability, and predictability in cash dividends, responding to the policy direction of increasing dividend frequency [2] - The initiative aims to optimize the dividend schedule, thereby enhancing the company's long-term investment value and improving investor experience [2]

Group 1 - The company, Hualan Biological Engineering, reported that as of September 19, 2025, it has over 147,000 investors [2]

Core Viewpoint - The company has successfully completed Phase I/II clinical trials for its recombinant Exendin-4-FC fusion protein injection, which is a treatment for type 2 diabetes, and is preparing to initiate Phase III clinical trials [1] Group 1: Product Development - The company is developing a new indication for its drug targeting overweight/obesity and has submitted a registration communication to the National Medical Products Administration, which has been accepted [1]

证券代码：002007 证券简称：华兰生物 公告编号：2025-037 华兰生物工程股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形； 2、本次股东会不涉及变更前次股东会决议的情形。 一、会议召开和出席情况 1、本次股东会的召开时间： 现场会议召开时间为：2025年9月22日下午14:30 网络投票时间：2025年9月22日。其中通过深圳证券交易所交易系统进行网络投 票的具体时间为2025年9月22日上午9:15—9:25,9:30—11:30和下午13:00—15:00； 通过深圳证券交易所互联网投票的具体时间为2025年9月22日09:15至15:00期间的 任意时间。 4、召集人：公司董事会 5、现场会议主持人：董事长安康先生 6、本次股东会的会议召集、召开程序符合有关法律、法规、规范性文件及《公 司章程》的有关规定。 7、会议出席情况： （1）出席会议总体情况 出席本次股东会现场会议和网络投票的股东及股东代理人共1,176人，代表股份 902,217,804 ...

关于 华兰生物工程股份有限公司 召开 2025 年第二次临时股东会的 法律意见书 安徽承义律师事务所 安徽承义律师事务所 中国.合肥市政务区怀宁路 200 号栢悦中心 5 楼 邮编: 230022 电话（Tel）: （86-551）65609815 传真（Fax）: （86-551）65608051 网址（Website）: www.chengyi-law.com 电子信箱（E-mail）：chengyilawyer@163.com 安徽承义律师事务所 关于华兰生物工程股份有限公司 召开 2025 年第二次临时股东会的法律意见书 （2025）承义法字第 00209 号 致：华兰生物工程股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 会规则》等法律法规和其他规范性文件的要求，安徽承义律师事务所接受华兰生 物工程股份有限公司（以下简称"公司"）的委托，指派鲍金桥、万晓宇律师（以 下简称"本律师"）就公司召开2025 年第二次临时股东会（以下简称"本次股东会"） 出具法律意见书。 一、本次股东会召集人资格和召集、召开的程序 经核查，本次股东会是由公司第九届董事会召集，公司已于 20 ...

Market Performance - The Medical Health Index (980016) closed at 7021.34 points, down 1.08%, with a trading volume of 33.906 billion yuan and a turnover rate of 1.07% [1] - Among the index constituents, 5 stocks rose while 45 stocks fell, with Yirui Technology leading the gainers at 1.82% and Changchun High-tech leading the decliners at 3.91% [1] Key Constituents - The top ten constituents of the Medical Health Index include: - WuXi AppTec (13.58% weight) at 108.75 yuan, up 1.23% with a market cap of 320.976 billion yuan - Hengrui Medicine (10.87% weight) at 69.65 yuan, down 2.03% with a market cap of 462.281 billion yuan - Mindray Medical (8.17% weight) at 235.00 yuan, down 1.18% with a market cap of 284.924 billion yuan - United Imaging Healthcare (4.14% weight) at 147.90 yuan, down 1.40% with a market cap of 121.893 billion yuan - Other notable constituents include Pianzai Shou, Yier Eye Hospital, Kelun Pharmaceutical, Xinhecheng, Fosun Pharma, and Yixiao Aoshi [1] Capital Flow - The Medical Health Index constituents experienced a net outflow of 2.29 billion yuan from institutional investors, while retail investors saw a net inflow of 2.013 billion yuan [3] - Notable capital flows include: - Mindray Medical with a net inflow of 98.789 million yuan from institutional investors and a net outflow of 10.5 million yuan from speculative funds - Changchun High-tech with a net inflow of 67.986 million yuan from institutional investors and a significant net outflow from speculative funds [3]

Market Overview - The biopharmaceutical sector experienced a decline of 1.9% on September 19, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable gainers included: - Aopumai (688293) with a closing price of 53.41, up 1.71% on a trading volume of 34,700 shares and a turnover of 189 million yuan [1] - Kexing Pharmaceutical (688136) closed at 41.88, up 1.70% with a trading volume of 45,300 shares and a turnover of 189 million yuan [1] - Significant decliners included: - Kanghong Pharmaceutical (002773) which fell 6.09% to a closing price of 37.00, with a trading volume of 94,100 shares and a turnover of 355 million yuan [2] - Changchun High-tech (000661) decreased by 3.91% to 125.22, with a turnover of 1.674 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 999.7 million yuan from institutional investors, while retail investors had a net inflow of 914 million yuan [2] - The table of capital flow indicates that: - Changchun High-tech had a net inflow of 67.986 million yuan from institutional investors [3] - Kanghua Biological (300841) experienced a net inflow of 11.825 million yuan from institutional investors [3]